<!-- vim: set tabstop=2 shiftwidth=2 expandtab: -->

---

Wirksamkeit der Impfung
-----------------------

> Dies ist das erste Medikament, dessen Versagen jenen angelastet wird, die es nicht genommen haben.
> <br/> - Dr. Robert Malone -

Uns wurde versprochen, daß die Impfung zu 95% schützt. Und zwar sowohl vor Infektion als auch vor
Weitergabe (Transmission) - vor schweren Krankheitsverläufen und Tod garantiert. Das
Bundesministerium für Gesundheit erklärte: „Geimpfte nehmen am Infektionsgeschehen nicht mehr teil.“
(Quelle mittlerweile nicht mehr verfügbar.) Auch heute noch wird dieser Weg von den meisten
Politikern propagiert. Doch was bringt die Impfung wirklich?

### Zulassungsstudien ###

Die Aussage zur Wirksamkeit von 95% entstammt der Phase-III-Studie von Pfizer/BioNTech:

- **Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin, et al.**:
  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, 31.12.2020 <br/>
  <https://www.nejm.org/doi/full/10.1056/NEJMoa2034577>
  > A total of 43,548 participants underwent randomization, of whom 43,448 received injections:
  > 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least
  > 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among
  > those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible
  > interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across
  > subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of
  > coexisting conditions. [...]
  >
  > Confirmed Covid-19 was defined according to the Food and Drug Administration (FDA) criteria as
  > the presence of at least one of the following symptoms: fever, new or increased cough, new or
  > increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell,
  > sore throat, diarrhea, or vomiting, combined with a respiratory specimen obtained during the
  > symptomatic period or within 4 days before or after it that was positive for SARS-CoV-2 by
  > nucleic acid amplification–based testing, either at the central laboratory or at a local testing
  > facility (using a protocol-defined acceptable test).

Diese hatte bei 21.728 Probanden der Placebogruppe 162 laborbestätigte Infektionen gefunden, bei den
21.720 Probanden der Impfgruppe dagegen nur 8. 8 von 162 macht 4,9% also 95,1% weniger. Klingt gut.
Wenn man den Menschen eine Effektivität von 95% erzählt, denken die meisten, daß 95 von 100
Geimpften geschützt wären und nur 5 nicht. Eine Impfung kann ja auch nicht perfekt sein. Das Problem
dabei: Was man denkt, entspricht der _absoluten Effektivität_. Die genannten 95% sind aber die
_relative Effektivität_. Bei der großen Anzahl der Probanden reduziert sich das _absolute Risiko_
tatsächlich von 0,75% (162/21.728) auf 0,04% (8/21.720), d.h. die _absolute Effektivität_ beträgt
nur 0,71% (0,75%-0,04%). Das bedeutet, daß man 141 Menschen impfen müßte damit einer geschützt wäre
(_Number Needed to Vaccinate_, NNTV=100%/0,71%=141), wobei die Schutzwirkung sich zudem nach der
Falldefinition der FDA richtet. Das bedeutet insbesondere, daß ein Nachweis eines Schutzes vor
Infektion oder Transmission gar nicht erbracht wurde. Bei dem Impfstoff von Moderna verhält es sich
ähnlich. Eine gute Erklärung bietet der Artikel von Multipolar (Quelle:
<https://multipolar-magazin.de/artikel/wirksamkeit-von-impfungen>).

Die Canadian Covid Care Alliance hat eine detaillierte Analyse jener Phase-III-Studie von Pfizer
vorgelegt, die auch erklären will warum das Ergebnis methodisch schlecht ist:

- **[Canadian Covid Care Alliance](https://www.canadiancovidcarealliance.org)**:
  THE PFIZER INOCULATIONS FOR COVID-19: MORE HARM THAN GOOD, 16.12.2021 <br/>
  <https://www.canadiancovidcarealliance.org/wp-content/uploads/2021/12/The-COVID-19-Inoculations-More-Harm-Than-Good-REV-Dec-16-2021.pdf>

Demnach hat der Wirkstoff von Pfizer/BioNTech neben seiner fragwürdigen Schutzwirkung das Risiko von
schwerer Krankheit und Tod (Folie 11 und 12) sogar erhöht. Ergebnisse zu Langzeitfolgen können nicht
vorliegen, da in der Studie vorzeitig nach 6 Monaten entblindet wurde, d.h. die Kontrollgruppe bekam
ein Impfangebot und wurde geimpft, womit zukünftige Vergleiche beider Gruppen unmöglich werden.

### Unabhängige Studien ###

Eine Forschergruppe aus Dänemark analysierte bereits 2021 die Art der gebildeten Antikörper nach
einer überstandenen Infektion mit SARS-CoV-2 und fand dabei, daß das Immunsystem IgG-Antikörper
bildet. Das ist verwunderlich, sollte es sich doch um IgM-Antikörper handeln, die normalerweise bei
einer Erstinfektion zu erwarten wären. Die gleiche Analyse kann man auch nach Verabreichung der
Impfstoffe durchführen. Wieder ließen sich IgG-Antikörper finden:

- **Alana F. Ogata, Chi-An Cheng, Michaël Desjardins, et al.**:
  Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected
    in the Plasma of mRNA-1273 Vaccine Recipients, 20.5.2021 <br/>
  <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab465/6279075>
  > Plasma antibodies IgG, IgA, and IgM were measured against spike, S1, RBD, and nucleocapsid.
  > Antibody levels measured on day zero represent the baseline level in each participant, all who
  > had no previous report of COVID-19 infection. In all 13 participants, as expected, IgG levels
  > against spike, S1, and RBD increased after the first injection, whereas IgG against nucleocapsid
  > showed no change over time. IgA is involved in early neutralization activity and is therefore
  > crucial to target potentially short-lived IgA responses. Our Simoa assays detected increased IgA
  > against spike, S1, and RBD after the first injection. Nine participants presented measurable IgG
  > levels against S1 and spike by day 14 after the first vaccine injection. Four participants,
  > showed a delayed IgG-S1 and IgG-spike response, which did not increase until day 28 after the
  > first injection. Nonetheless, all participants showed additional boost in IgG-S1 after the
  > second injection.

- **Fatima Amanat, Mahima Thapa, Tinting Lei, et al.**:
  SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2, 8.6.2021 <br/>
  <https://www.cell.com/cell/fulltext/S0092-8674(21)00706-6>
  > _The spike-reactive plasmablast response is dominated by IgG1+ cells and is comprised of a
  > mixture of cells with low and high levels of somatic hypermutation (SHM)._ [...] We next
  > examined the isotype and IgG subclass distribution among the recovered sequences. IgG1 was by
  > far the most dominant isotype in the three vaccinees.

- **Adam V. Wisnewski, Julian Campillo Luna, Carrie A. Redlich**:
  Human IgG and IgA responses to COVID-19 mRNA vaccines, 16.6.2021 <br/>
  <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0249499>
  > SARS-CoV-2 spike antigen-specific IgG and IgA elicited by infection mediate viral neutralization
  > and are likely an important component of natural immunity, however, limited information exists
  > on vaccine induced responses. We measured COVID-19 mRNA vaccine induced IgG and IgA in serum
  > serially, up to 145 days post vaccination in 4 subjects. Spike antigen-specific IgG levels rose
  > exponentially and plateaued 21 days after the initial vaccine dose. After the second vaccine
  > dose IgG levels increased further, reaching a maximum approximately 7–10 days later, and
  > remained elevated (average of 58% peak levels) during the additional >100 day follow up period.
  > COVID-19 mRNA vaccination elicited spike antigen-specific IgA with similar kinetics of induction
  > and time to peak levels, but more rapid decline in serum levels following both the 1st and 2nd
  > vaccine doses (<18% peak levels within 100 days of the 2nd shot). _The data demonstrate COVID-19
  > mRNA vaccines effectively induce spike antigen specific IgG and IgA and highlight marked
  > differences in their persistence in serum._

Aus Sicht des Immunsystems handelt es sich bei der Impfung folglich nicht um einen Erstkontakt mit
einem neuen Krankheitserreger. Das führt den Sinn einer Impfung ad absurdum, da dieser eigentlich
darin besteht, einen Erstkontakt mit einer relativ harmlosen Attrappe vorwegzunehmen. Damit soll das
Immunsystem dazu gebracht werden, Gedächtniszellen zu bilden, um bei erneutem Kontakt mit dem
eigentlichen Krankheitserreger die Abwehrreaktion schneller und effizienter einleiten zu können.

Weitere unabhängige Studien - von den eingangs erwähnten Stellungnahmen bereits referenziert - haben
zwischenzeitlich auch die anderen ursprünglichen Werbeversprechen widerlegt: (a) Die Impfung schützt
nicht vor Infektion. (b) Die Virenlast bei Geimpften ist genau so hoch wie bei Ungeimpften (kein
Schutz vor Transmission, kein Fremdschutz), beispielsweise:

- **Catherine M. Brown, Johanna Vostok, Hillary Johnson, et al.**:
  Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections,
    Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021, 6.8.2021 <br/>
  <https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm>
  > In July 2021, following multiple large public events in a Barnstable County, Massachusetts,
  > town, 469 COVID-19 cases were identified among Massachusetts residents who had traveled to the
  > town during July 3–17; 346 (74%) occurred in fully vaccinated persons. Testing identified the
  > Delta variant in 90% of specimens from 133 patients. _Cycle threshold values were similar among
  > specimens from patients who were fully vaccinated and those who were not._

- **Charlotte B. Acharya, John Schrom, Anthea M. Mitchell, et al.**:
  No Significant Difference in Viral Load Between Vaccinated and Unvaccinated,
    Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant, 5.10.2021 <br/>
  <https://www.medrxiv.org/content/10.1101/2021.09.28.21264262v2.full>
  > _We found no significant difference in cycle threshold values between vaccinated and
  > unvaccinated, asymptomatic and symptomatic groups infected with SARS-CoV-2 Delta._ Given the
  > substantial proportion of asymptomatic vaccine breakthrough cases with high viral levels,
  > interventions, including masking and testing, should be considered for all in settings with
  > elevated COVID-19 transmission.

- **Anika Singanayagam, Seran Hakki, Jake Dunning, et al.**:
  Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in
    vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study, 29.10.2021 <br/>
  <https://www.thelancet.com/journals/laninf/article/PIIS1473-30992100648-4/fulltext>
  > Although peak viral load did not differ by vaccination status or variant type, it increased
  > modestly with age (difference of 0.39 [95% credible interval –0.03 to 0.79] in peak log10 viral
  > load per mL between those aged 10 years and 50 years). Fully vaccinated individuals with delta
  > variant infection had a faster (posterior probability >0.84) mean rate of viral load decline
  > (0.95 log10 copies per mL per day) than did unvaccinated individuals with pre-alpha (0.69),
  > alpha (0.82), or delta (0.79) variant infections. Within individuals, faster viral load growth
  > was correlated with higher peak viral load (correlation 0.42 [95% credible interval 0.13 to
  > 0.65]) and slower decline (–0.44 [–0.67 to –0.18]). [...] Vaccination reduces the risk of delta
  > variant infection and accelerates viral clearance. _Nonetheless, fully vaccinated individuals
  > with breakthrough infections have peak viral load similar to unvaccinated cases and can
  > efficiently transmit infection in household settings, including to fully vaccinated contacts._
  > Host–virus interactions early in infection may shape the entire viral trajectory.

- **Matan Levine-Tiefenbrun, Idan Yelin, Hillel Alapi, et al.**:
  Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination
    and booster with BNT162b2, 2.11.2021 <br/>
  <https://www.nature.com/articles/s41591-021-01575-4>
  > By analyzing viral loads of over 16,000 infections during the current, Delta-variant-dominated
  > pandemic wave in Israel, we found that BTIs [breakthrough infections] in recently fully
  > vaccinated individuals have lower viral loads than infections in unvaccinated individuals.
  > _However, this effect starts to decline 2 months after vaccination and ultimately vanishes 6
  > months or longer after vaccination._ Notably, we found that the effect of BNT162b2 on reducing
  > BTI viral loads is restored after a booster dose. These results suggest that BNT162b2 might
  > decrease the infectiousness of BTIs even with the Delta variant, and that, although this
  > protective effect declines with time, it can be restored, at least temporarily, with a third,
  > booster, vaccine dose.

- **Kasen K. Riemersma, Brittany E. Grogan, Amanda Kita-Yarbro, et al.**:
  Shedding of Infectious SARS-CoV-2 Despite Vaccination, 6.11.2021 <br/>
  <https://www.medrxiv.org/content/10.1101/2021.07.31.21261387v6.full>
  > RT-PCR Ct values <25 had previously been associated with shedding of infectious SARS-CoV-2. _We
  > observed low Ct values (<25) in 212 of 310 fully vaccinated (68%) and 246 of 389 (63%)
  > unvaccinated individuals. Low Ct values were detected in vaccinated people regardless of
  > symptoms at the time of testing._ Ct values <25 were detected in 7 of 24 unvaccinated (29%; CI:
  > 13-51%) and 9 of 11 fully vaccinated asymptomatic individuals (82%; CI: 48-97%), and 158 of 232
  > unvaccinated (68%, CI: 62-74%) and 156 of 225 fully vaccinated (69%; CI: 63-75%) symptomatic
  > individuals. Testing a subset of these low-Ct samples revealed infectious SARS-CoV-2 in 15 of 17
  > specimens (88%) from unvaccinated individuals and 37 of 39 (95%) from vaccinated people.
  > Infectious virus was detected in the sole specimen tested from an asymptomatic fully vaccinated
  > individual. _Although few asymptomatic individuals were sampled, these results indicate that
  > even asymptomatic, fully vaccinated people might shed infectious SARS-CoV-2. To determine
  > whether infectious virus titers differed in vaccinated and unvaccinated persons, we performed
  > plaque assays on an additional set of 48 samples with Ct <25, finding no difference in
  > infectious virus titer between groups._ Notably time from symptom onset to testing did not vary
  > by vaccination status, suggesting that our observations are not confounded by biases in
  > test-seeking behavior between vaccinated and unvaccinated persons (p=0.40).

Allein die Tatsache, daß wir nach 3G (Geimpft/Genesen/Getestet) wieder Lockdowns und verschärfte
Maßnahmen wie 2G und 2G+ benötigen, sollte diese Punkte eindrucksvoll belegen. Damit ist das
Argument der Impfung aus Solidarität, daß noch immer bemüht wird, nicht mehr gerechtfertigt -
Grundrechtseinschränkungen wie 3G, 2G und 2G+ ohnehin nicht. Das sollte nicht verwundern: Es gibt
Viren, die nach erfolgter Infektion eine Inkubationszeit benötigen bis der neue Wirt selbst wieder
infektiös wird. Kann man in diesem Zeitraum die Vermehrung verhindern, wird diese Schwelle nie
erreicht (sterile Immunität). Das ist bei Atemwegsviren aber nicht der Fall. Außerdem führen die
Impfstoffe - im Gegensatz zu einer natürlichen Infektion - nur zu Antikörpern im Blutserum, nicht
aber in den Schleimhäuten der Atemwege. Und ganz im Allgemeinen kann man alles was man einatmet auch
sofort wieder ausatmen. Eine konsequente Schlußfolgerung findet sich in:

- **Anonymous, Prof. Dr. Sucharit Bhakdi, Prof. Dr. Michael Palmer**:
  Why intramuscular COVID-19 vaccination must fail, 7.12.2021 <br/>
  <https://doctors4covidethics.org/immunology-101-why-intramuscular-covid-19-vaccination-must-fail/>
  > _All of the currently used COVID vaccines are applied by intramuscular injection, and they are
  > therefore unable to prevent infection of the upper airways with the SARS-CoV-2 virus._ In fact,
  > in their clinical trials, none of the manufacturers even attempted to demonstrate efficacy
  > against infection or transmission in their clinical trials, and the total lack of efficacy in
  > the real world has since been documented in a large study published by the CDC. The vaccines
  > can, however, lead to severe respiratory immune disease, including Th2-type immunopathology and
  > autoimmunity. _When factoring in the large number of adverse events that are being reported with
  > the current vaccines and the low case fatality rate of COVID-19, which we have discussed
  > elsewhere, it is clearly more scientific and more reasonable to strive for herd immunity by
  > natural infection rather than vaccination._

Was noch übrig bleibt wäre ein gewisser Schutz vor schwerer Symptomatik (Eigenschutz). Das RKI
schreibt dazu in seinem aktuellen Wochenbericht vom 6.1.2022 (Quelle:
<https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenbericht_2022-01-06.pdf?__blob=publicationFile>):

> Die nach der Farrington-Methode geschätzte Effektivität einer Grundimmunisierung gegenüber einer
> symptomatischen COVID-19-Erkrankung lag für die vergangenen 4 Wochen (Mittelwert der MW 49 bis 52)
> in der Altersgruppe 12-17 Jahre bei ca. 81%, in der Altersgruppe 18-59 Jahre bei ca. 62% und in
> der Altersgruppe ab 60 Jahre bei ca. 71%. Die mit derselben Methode geschätzte Effektivität einer
> Auffrischimpfung gegenüber einer symptomatischen COVID-19-Erkrankung lag für die vergangenen 4
> Wochen in der Altersgruppe 18-59 Jahre bei 89% und in der Altersgruppe ab 60 Jahre bei ca. 93%.

Vom RKI unerwähnt bleibt die Verzerrung, die durch die politisch verordneten Maßnahmen sowie die
kreative Zählweise des RKI selbst entstehen. Da bei 3G sowie dem Testmarathon in Schulen und
Kindergärten Personengruppen mit niedrigster Impfquote und damit bevorzugt Ungeimpfte getestet
werden, kann man annehmen, daß diese im Ergebnis auch überrepräsentiert sind. Geimpfte müssen gemäß
2G-Regeln schließlich nicht getestet werden. Desweiteren beginnt der Impfschutz offiziell erst 2
Wochen nach der zweiten Impfung, so daß etwaige Infektionen bis zu diesem Zeitpunkt noch den
Ungeimpften zugerechnet werden. Für weitere Verzerrung sorgt die kreative Idee nur Geimpfte mit
Symptomen als Impfdurchbrüche zu werten, wohingegen bei Ungeimpften bereits ein positiver PCR-Test
ausreichend ist. Normalerweise würde man die gleichen Kriterien ansetzen, wenn man beabsichtigte ein
valides Ergebnis zu erhalten. Aus diesen Gründen dürfte die vom RKI berechnete Effektivität um einen
unbekannten Faktor zu hoch ausfallen.

### Dauer der Schutzwirkung ###

Aber wenigstens mehr als nichts. Die Schutzwirkung ist allerdings nicht so lange anhaltend wie
versprochen. Zum einen konnten die Studien keine Schutz während der ersten 2 Wochen nach der ersten
Dosis feststellen; zum Anderen schwindet der Schutz vor allem bei der eigentlichen Zielgruppe, den
Älteren und Schwächeren, am schnellsten:

- **Peter Nordström, Marcel Ballin, Anna Nordström**:
  Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization,
    and Death Up to 9 Months: A Swedish Total-Population Cohort Study, 25.10.2021 <br/>
  <https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3949410>
  > Vaccine effectiveness of BNT162b2 against infection waned progressively from 92% (95% CI, 92-93,
  > P<0.001) at day 15-30 to 47% (95% CI, 39-55, P<0.001) at day 121-180, and from day 211 and
  > onwards no effectiveness could be detected (23%; 95% CI, -2-41, P=0.07). The effectiveness waned
  > slightly slower for mRNA-1273, being estimated to 59% (95% CI, 18-79) from day 181 and onwards.
  > In contrast, effectiveness of ChAdOx1 nCoV-19 was generally lower and waned faster, with no
  > effectiveness detected from day 121 and onwards (-19%, 95% CI, -97-28), whereas effectiveness
  > from heterologous ChAdOx1 nCoV-19 / mRNA was maintained from 121 days and onwards (66%; 95% CI,
  > 41-80). _Overall, vaccine effectiveness was lower and waned faster among men and older
  > individuals. For the outcome severe Covid-19, effectiveness waned from 89% (95% CI, 82-93,
  > P<0.001) at day 15-30 to 42% (95% CI, -35-75, P=0.21) from day 181 and onwards, with sensitivity
  > analyses showing notable waning among men, older frail individuals, and individuals with
  > comorbidities._

- **Hiam Chemaitelly, Patrick Tang, Mohammad R. Hasan, et al.**:
  Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar, 9.12.2021 <br/>
  <https://www.nejm.org/doi/full/10.1056/NEJMoa2114114>
  > Estimated BNT162b2 effectiveness against any SARS-CoV-2 infection was negligible in the first 2
  > weeks after the first dose. It increased to 36.8% (95% confidence interval [CI], 33.2 to 40.2)
  > in the third week after the first dose and reached its peak at 77.5% (95% CI, 76.4 to 78.6) in
  > the first month after the second dose. _Effectiveness declined gradually thereafter, with the
  > decline accelerating after the fourth month to reach approximately 20% in months 5 through 7
  > after the second dose._ Effectiveness against symptomatic infection was higher than
  > effectiveness against asymptomatic infection but waned similarly. Variant-specific effectiveness
  > waned in the same pattern. Effectiveness against any severe, critical, or fatal case of Covid-19
  > increased rapidly to 66.1% (95% CI, 56.8 to 73.5) by the third week after the first dose and
  > reached 96% or higher in the first 2 months after the second dose; effectiveness persisted at
  > approximately this level for 6 months.

- **Einav G. Levin, Yaniv Lustig, Carmit Cohen, et al.**:
  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months, 9.12.2021 <br/>
  <https://www.nejm.org/doi/full/10.1056/NEJMoa2114583>
  > The study included 4868 participants, with 3808 being included in the linear mixed-model
  > analyses. The level of IgG antibodies decreased at a consistent rate, whereas the neutralizing
  > antibody level decreased rapidly for the first 3 months with a relatively slow decrease
  > thereafter. Although IgG antibody levels were highly correlated with neutralizing antibody
  > titers (Spearman’s rank correlation between 0.68 and 0.75), the regression relationship between
  > the IgG and neutralizing antibody levels depended on the time since receipt of the second
  > vaccine dose. Six months after receipt of the second dose, neutralizing antibody titers were
  > substantially lower among men than among women (ratio of means, 0.64; 95% confidence interval
  > [CI], 0.55 to 0.75), lower among persons 65 years of age or older than among those 18 to less
  > than 45 years of age (ratio of means, 0.58; 95% CI, 0.48 to 0.70), and lower among participants
  > with immunosuppression than among those without immunosuppression (ratio of means, 0.30; 95% CI,
  > 0.20 to 0.46).
  >
  > _Six months after receipt of the second dose of the BNT162b2 vaccine, humoral response was
  > substantially decreased, especially among men, among persons 65 years of age or older, and among
  > persons with immunosuppression._

Alles zusammen genommen taugt die Impfung demnach ungefähr ein halbes Jahr lang als Schutz vor einem
schweren Verlauf, wenn man überhaupt zu einer Personengruppe gehörte, die davon betroffen wäre – zum
Schutz der Gesellschaft aus Solidarität hingegen nicht. Außerdem müßte man bei einer derartig kurzen
Wirkdauer permanent nachimpfen, womit aber andererseits (a) eine Schädigung des Immunsystems und
damit eine Verschlechterung der Wirkung zu erwarten wäre (Quelle:
<https://news.bloomberglaw.com/coronavirus/repeat-booster-shots-spur-europe-warning-on-immune-system-risks>)
sowie (b) sich Nebenwirkungen akkumulieren können. Damit verschiebt sich das
Kosten-Nutzen-Verhältnis langfristig zu Ungunsten der Impfung.

### Vergleich mit natürlicher Immunität ###

Im Vergleich zu einer auf natürlichem Wege entstandenen Immunität schneidet die Schutzwirkung der
Impfstoffe schlechter ab:

- **Sivan Gazit, Roei Shlezinger, Galit Perez, et al.**:
  Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity:
    reinfections versus breakthrough infections, 25.8.2021 <br/>
  <https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v1.full>
  > SARS-CoV-2-naïve vaccinees had a 13.06-fold (95% CI, 8.08 to 21.11) increased risk for
  > breakthrough infection with the Delta variant compared to those previously infected, when the
  > first event (infection or vaccination) occurred during January and February of 2021. The
  > increased risk was significant (P<0.001) for symptomatic disease as well. When allowing the
  > infection to occur at any time before vaccination (from March 2020 to February 2021), evidence
  > of waning natural immunity was demonstrated, though SARS-CoV-2 naïve vaccinees had a 5.96-fold
  > (95% CI, 4.85 to 7.33) increased risk for breakthrough infection and a 7.13-fold (95% CI, 5.51
  > to 9.21) increased risk for symptomatic disease. SARS-CoV-2-naïve vaccinees were also at a
  > greater risk for COVID-19-related-hospitalizations compared to those that were previously
  > infected.
  >
  > _This study demonstrated that natural immunity confers longer lasting and stronger protection
  > against infection, symptomatic disease and hospitalization caused by the Delta variant of
  > SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity. Individuals who were
  > both previously infected with SARS-CoV-2 and given a single dose of the vaccine gained
  > additional protection against the Delta variant._

- **Rebecca Grant, Tiffany Charmet, Laura Schaeffer, et al.**:
  Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness:
    Results from a nationwide case-control study in France, 26.11.2021 <br/>
  <https://www.sciencedirect.com/science/article/pii/S2666776221002647>
  > We found strong protection against symptomatic Delta infection for those with prior infection
  > whether it was recent (2-6 months) (95%; 95%CI:90-97) or associated with one dose (85%;
  > 95%CI:78-90) or two doses of mRNA vaccine (96%; 95%CI:87-99). _For those without past infection,
  > protection was lower with two doses of mRNA vaccine (67%; 95%CI:63-71)._

- **Yair Goldberg, Micha Mandel, Yinon M. Bar-On, et al.**:
  Protection and waning of natural and hybrid COVID-19 immunity, 5.12.2021 <br/>
  <https://www.medrxiv.org/content/10.1101/2021.12.04.21267114v1.full>
  > Confirmed infection rates increased according to time elapsed since the last immunity-conferring
  > event in all cohorts. For unvaccinated previously infected individuals they increased from 10.5
  > per 100,000 risk-days for those previously infected 4-6 months ago to 30.2 for those previously
  > infected over a year ago. For individuals receiving a single dose following prior infection they
  > increased from 3.7 per 100,000 person days among those vaccinated in the past two months to 11.6
  > for those vaccinated over 6 months ago. For vaccinated previously uninfected individuals the
  > rate per 100,000 person days increased from 21.1 for persons vaccinated within the first two
  > months to 88.9 for those vaccinated more than 6 months ago.
  >
  > _Protection from reinfection decreases with time since previous infection, but is, nevertheless,
  > higher than that conferred by vaccination with two doses at a similar time since the last
  > immunity-conferring event._

- **Ariel Israel, Yotam Shenhar, Ilan Green, et el.**:
  Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine
    or SARS-CoV-2 Infection, 31.12.2021 <br/>
  <https://www.mdpi.com/2076-393X/10/1/64/htm>
  > A total of 2653 individuals fully vaccinated by two doses of vaccine during the study period and
  > 4361 convalescent patients were included. Higher SARS-CoV-2 IgG antibody titers were observed in
  > vaccinated individuals (median 1581 AU/mL IQR [533.8–5644.6]) after the second vaccination than
  > in convalescent individuals (median 355.3 AU/mL IQR [141.2–998.7]; p < 0.001). _In vaccinated
  > subjects, antibody titers decreased by up to 38% each subsequent month while in convalescents
  > they decreased by less than 5% per month._ Six months after BNT162b2 vaccination 16.1% subjects
  > had antibody levels below the seropositivity threshold of <50 AU/mL, while only 10.8% of
  > convalescent patients were below <50 AU/mL threshold after 9 months from SARS-CoV-2 infection.
  > _This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have
  > different kinetics of antibody levels compared to patients who had been infected with the
  > SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first
  > group._

Dies ist aus oben genannten Gründen plausibel aber auch, da (a) Antikörper nach einiger Zeit
abgebaut werden und (b) die von der Impfung verliehene Immunität vor allem auf der Bildung von
Antikörpern gegen zwei virale Angriffsziele beruht: die Spike-Proteine sowie die
Rezeptor-Bindungs-Domäne. Coronaviren haben jedoch insgesamt 20 verschiedene Antigene
beziehungsweise Proteine, die das Immunsystem als fremd erkennen könnte. Eine natürliche Immunität
ist folglich deutlich breiter aufgestellt. Entsprechende Antikörpertiter konnten sogar noch 14
Monate lang - der Länge der Beobachtungsdauer - ohne erkennbares Ende nachgewiesen werden:

- **Heinrich Scheiblauer, Claudius Micha Nübling, Timo Wolf, et al.**:
  Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of
    detection are predominantly determined by avidity progression and test design, 15.21.2021 <br/>
  <https://www.sciencedirect.com/science/article/pii/S138665322100319X>
  > Sensitivity at 30–60 days post symptom onset (pso) for TAb-S/RBD, TAb-N, IgG-S, IgG-N, IgA-S,
  > IgM-RBD, and NAb was 96.6%, 99.5%, 89.7%, 94.3%, 80.9%, 76.9% and 92.8%, respectively. Follow-up
  > 430 days pso revealed: TAb-S/RBD increased slightly (100.0%); TAb-N decreased slightly (97.1%);
  > IgG-S and IgA-S decreased moderately (81.4%, 65.7%); NAb remained positive (94.3%), slightly
  > decreasing in activity after 300 days; there was correlation with IgG-S (Rs = 0.88) and IgA-S
  > (Rs = 0.71); IgG-N decreased significantly from day 120 (15.7%); IgM-RBD dropped after 30–60
  > days (22.9%). _High antibody avidity developed against S/RBD steadily with time in 94.3% of
  > patients after 430 days._ This correlated with persistent antibody detection depending on
  > antibody-binding efficiency of the test design. Severe COVID-19 correlated with earlier and
  > higher antibody response, mild COVID-19 was heterogeneous with a wide range of antibody
  > reactivities. Specificity of the tests was >=99%, except for IgA (96%).

### Nutzen der Impfung ###

Bei Autoren, die nicht von Pfizer bezahlt und auch nicht beim RKI angestellt sind, fällt die Analyse
des Risiko-Nutzen-Verhältnisses schon bei der Deltavariante vernichtend aus:

- **Harald Walach, Rainer J. Klement, Wouter Aukema**:
  The Safety of COVID-19 Vaccinations — Should We Rethink the Policy?, Aug 2021 <br/>
  <https://www.researchgate.net/publication/354223836_The_Safety_of_COVID-19_Vaccinations_-_Should_We_Rethink_the_Policy_newly_and_independently_peer-reviewed_version>
  > The NNTV is between 200 and 700 to prevent one case of COVID-19 for the mRNA vaccine marketed by
  > Pfizer. NNTV to prevent one death is between 9,000 and 100,000 (95% confidence interval), with
  > 16,000 as a point estimate. We observed strong variability in the number of Individual Case
  > Safety Reports (ICSRs) per 100,000 vaccine doses across all EU member states. The estimate for
  > the number of ICSRs per 100,000 vaccinations derived from the Lareb database was approximately
  > 700\. Among those, there were 16 serious ICSRs, and the number of ICSRs reporting fatal
  > side-effects was at 4.11/100,000 vaccinations. _Thus, for 6 (95% CI 2–11) deaths prevented by
  > vaccination, there were approximately 4 deaths reported to Dutch Lareb that occurred after
  > vaccination, yielding a potential risk/benefit ratio of 2:3._

Auch Autoren, die sich mit der Reduktion der Sterblichkeit in Bezug zur Impfquote befasst haben,
haben wider Erwarten keine Negativkorrelation gefunden - allenfalls eine leicht positive, so daß sie
folgern:

- **S. V. Subramanian, Akhil Kumar**:
  Increases in COVID‐19 are unrelated to levels of vaccination across 68 countries and
    2947 counties in the United States, 30.9.2021 <br/>
  <https://link.springer.com/article/10.1007/s10654-021-00808-7>
  > At the country-level, there appears to be no discernable relationship between percentage of
  > population fully vaccinated and new COVID-19 cases in the last 7 days. In fact, the trend line
  > suggests a marginally positive association such that countries with higher percentage of
  > population fully vaccinated have higher COVID-19 cases per 1 million people. Notably, Israel
  > with over 60% of their population fully vaccinated had the highest COVID-19 cases per 1 million
  > people in the last 7 days. The lack of a meaningful association between percentage population
  > fully vaccinated and new COVID-19 cases is further exemplified, for instance, by comparison of
  > Iceland and Portugal. Both countries have over 75% of their population fully vaccinated and have
  > more COVID-19 cases per 1 million people than countries such as Vietnam and South Africa that
  > have around 10% of their population fully vaccinated. [...]
  >
  > The sole reliance on vaccination as a primary strategy to mitigate COVID-19 and its adverse
  > consequences needs to be re-examined, especially considering the Delta (B.1.617.2) variant and
  > the likelihood of future variants. Other pharmacological and non-pharmacological interventions
  > may need to be put in place alongside increasing vaccination rates. Such course correction,
  > especially with regards to the policy narrative, becomes paramount with emerging scientific
  > evidence on real world effectiveness of the vaccines. For instance, in a report released from
  > the Ministry of Health in Israel, the effectiveness of 2 doses of the BNT162b2 (Pfizer-BioNTech)
  > vaccine against preventing COVID-19 infection was reported to be 39%, substantially lower than
  > the trial efficacy of 96%. It is also emerging that immunity derived from the Pfizer-BioNTech
  > vaccine may not be as strong as immunity acquired through recovery from the COVID-19 virus. A
  > substantial decline in immunity from mRNA vaccines 6-months post immunization has also been
  > reported.

### Omikron ###

Gegenüber der Omikronvariante fällt der Schutz selbst laut RKI gering aus. Der Wochenbericht vom
6.1.2022 enthält die folgende Tabelle zu den Omikronfällen der Kalenderwochen 49 bis 52/2021
(Quelle:
<https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenbericht_2022-01-06.pdf?__blob=publicationFile>).

<a href="images/Omikronfaelle.png">
  <img src="images/Omikronfaelle.png" width="800">
</a>

Demnach sind Ungeimpfte teilweise unterrepräsentiert. Der Anteil der Ungeimpften der 3 höheren
Altersgruppen (außer 5-11 Jahre) in der Gesellschaft beträgt 40%/22%/12%. Der Anteil an
symptomatischen Fällen beträgt 44,1%/**14,6%**/13,2%, der Anteil an hospitalisierten Fällen
40,0%/23,0%/27,9%. Konsequenterweise schreibt das RKI auch (Quelle: selber Bericht):

> Die Wirksamkeit der einzelnen Impfstoffe gegen die Omikronvariante ist noch nicht endgültig zu
> beurteilen. Das Robert Koch-Institut schätzt die Gefährdung durch COVID-19 für die Gesundheit der
> Bevölkerung in Deutschland insgesamt als sehr hoch ein. Ursächlich hierfür ist das Auftreten und
> die rasante Verbreitung der Omikronvariante, die sich nach derzeitigem Kenntnisstand (aus anderen
> Ländern) deutlich schneller und effektiver verbreitet als die bisherigen Virusvarianten. Dadurch
> ist mit einer schlagartigen Erhöhung der Infektionsfälle zu rechnen und es kann zu einer schnellen
> Überlastung des Gesundheitssystems und ggf. weiterer Versorgungsbereiche kommen. Die
> Infektionsgefährdung wird für die Gruppe der Ungeimpften als sehr hoch, für die Gruppen der
> Genesenen und Geimpften mit Grundimmunisierung (zweimalige Impfung) als hoch und für die Gruppe
> der Geimpften mit Auffrischimpfung (dreimalige Impfung) als moderat eingeschätzt.

Wie man - bis auf den ersten Satz - zu so einem Urteil kommen kann ist völlig unklar nachdem Omikron
die Gefährlichkeit der endemischen Influenzaviren unterschritten hat. Auch die Altersstratifizierung
der Symptomatik wird komplett ignoriert. Zu einer Überlastung des Gesundheitssystems ist es in
anderen Ländern, wo Omikron bereits dominant ist, auch nicht gekommen.

(Übrigens ist Infektionsgefährdung auch ein schönes deutsches Wort. Was ist das? Die Gefahr des
Auftretens einer - zumeist symptomlosen - Infektion, oder die Gefahr hervorgerufen durch die
Infektion?)

Die Autoren einer Studie der Universität Oxford fanden jedenfalls einen erheblichen Rückgang der
Wirksamkeit der Impfstoffe bis hin zum Ausbleiben jeglicher Wirksamkeit gegenüber der
Omikronvariante:

- **Wanwisa Dejnirattisai, Robert H. Shaw, Piyada Supasa, et al.**:
  Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum, 11.12.2021 <br/>
  <https://www.medrxiv.org/content/10.1101/2021.12.10.21267534v1.full>
  > In this report, we present live neutralisation titres against SARS-CoV-2 Omicron variant,
  > compared with neutralisation against Victoria, Beta and Delta variants. Sera from day-28 post
  > second-dose were obtained from participants in the Com-COV2 study who had received a two-dose
  > COVID-19 vaccination schedule with either AstraZeneca (AZD1222) or Pfizer (BNT162b2) vaccines.
  > There was a substantial fall in neutralisation titres in recipients of both AZD1222 and BNT16b2
  > primary courses, with evidence of some recipients failing to neutralise at all. This will likely
  > lead to increased breakthrough infections in previously infected or double vaccinated
  > individuals, which could drive a further wave of infection, although there is currently no
  > evidence of increased potential to cause severe disease, hospitalization or death.

Eine Impfung, die vor so gut wie nichts schützt und dabei bald noch schneller runter ist als der
Akku meines Telefons, taugt einfach nichts. Vielleicht sollte man sich vor Verabschiedung einer
Impfpflicht zunächst überlegen was man eigentlich damit erreichen will. Ich fasse zusammen: Gerade
jetzt ist der denkbar sinnloseste Zeitpunkt sich impfen zu lassen. Wir haben Impfstoffe, die nicht
an die Alpha- oder Deltavariante angepasst waren und bereits grandios versagt haben. Wieso benötigen
wir überhaupt Booster? Wo bleibt der versprochene lebenslange Schutz? Und selbige Impfstoffe nutzen
bei der Omikronvariante fast nichts mehr. Wozu sollte ich mich jetzt impfen lassen, wenn Omikron in
ein paar Wochen Delta verdrängt haben wird und die kommende Dreifach-Omikron-Impfung bereits
angekündigt ist? (Quelle:
<https://www.tagesschau.de/wirtschaft/unternehmen/biontech-omikron-impfstoff-101.html>) Außerdem
gelten ab jetzt mit 2G+ nur noch Geboosterte als vollwertige Menschen. Das erhöht die Motivation
auch nicht besonders.
